Abstract

Parkinson’s disease (PD) involves the neurodegeneration of dopaminergic neurons, which is accompanied by neuroinflammation in the substantia nigra (SN). Mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exhibit microglial activation-induced inflammation as well as DA neuronal damage. In this study, treatment with Pogostemon Cabin (PC) prevented the degeneration of the Dopamine (DA) neurons in the substantia nigra (SN). This neuro-protective effect of PC was associated with microglial deactivation and a reduction in CD4+ T cell infiltration. Therefore, the results of this study suggest that PC exerts its neuroprotective function via its anti-inflammatory properties and that PC could be employed as a novel therapeutic agent for PD associated with neuroinflammation and CD4+ T cell infiltration into central nerve system.

Author keywords

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); CD4+ T cells; Microglia; Neuroinflammation; Parkinson’s disease (PD); Pogostemon Cabin (PC); Tyrosine hydroxylase (TH)

Indexed keywords

EMTREE drug terms: 1,2,3,6 tetrahydro 1 methyl 4 phenylpyridine; antiinflammatory agent; herbaceous agent; neuroprotective agent; plant extract

EMTREE medical terms: animal experiment; animal model; animal tissue; antiinflammatory activity; Article; CD4+ T lymphocyte; cell survival; controlled study; dopaminergic nerve cell; immunohistochemistry; lymphocytic infiltration; male; microglia; mouse; nervous system inflammation; neuroprotection; nonhuman; Parkinson disease; Pogostemon; Pogostemon cabin; substantia nigra

Chemicals and CAS Registry Numbers: 1,2,3,6 tetrahydro 1 methyl 4 phenylpyridine, 28289-54-5